Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 543-544

  Dicembrini, Ilaria ^a   Mannucci, Edoardo ^a  

^a Careggi Teaching Hospital   (Italy)

Author keywords

Dipeptidyl Peptidase 4 inhibitors; Myocardial infarction; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; PIPERIDINE DERIVATIVE; URACIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY RISK; DIABETES MELLITUS; DISEASE DURATION; DRUG SAFETY; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; META ANALYSIS (TOPIC); MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; INCIDENCE; META ANALYSIS; METHODOLOGY; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT SELECTION; TIME;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PATIENT OUTCOME ASSESSMENT; PATIENT SELECTION; PIPERIDINES; RESEARCH DESIGN; TIME FACTORS; URACIL;

EID: 84933563982     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.034     Document Type: Article

References (6)

1. M. Monami, B. Ahrèn, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials, Diabetes Obes. Metab. 15 (2013) 112-120.
2. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, SAVOR-TIMI 53 Steering Committee and Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N. Engl. J. Med. 369 (2013) 1317-1326.
3. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, EXAMINE Investigators, Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N. Engl. J. Med. 369 (2013) 1327-1335.
4. G. Savarese, P. Perrone-Filardi, C. D'Amore, C. Vitale, B. Trimarco, L. Pani, G.M.C. Rosano, Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis, Int. J. Cardiol. 181 (2015) 239-244.
5. J. McMurray, The vildagliptin in ventricular dysfunction diabetes trial (VIVIDD), Presented at the European Heart Failure Meeting, Lisbon, May 2013, 2013.
6. M. Monami, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials, Nutr. Metab. Cardiovasc. Dis. 24 (2014) 689-697.